ALX Oncology (NASDAQ:ALXO) CEO Jason Lettmann Buys 21,070 Shares

Key Points

• CEO Jason Lettmann of ALX Oncology purchased 21,070 shares at an average price of $1.07, increasing his ownership by 9.90% to a total of 233,958 shares valued at approximately $250,335.06.
• ALX Oncology's stock saw a 3.8% increase recently, reaching $1.09, with a market capitalization of $58.37 million and a PE ratio of -0.50.
• Despite recent transactions, the company reported earnings per share of ($0.49), missing estimates, and analysts project an EPS of -2.76 for the current fiscal year.

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann purchased 21,070 shares of ALX Oncology stock in a transaction on Tuesday, September 16th. The shares were purchased at an average cost of $1.07 per share, with a total value of $22,544.90. Following the transaction, the chief executive officer owned 233,958 shares in the company, valued at approximately $250,335.06. The trade was a 9.90% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jason Lettmann also recently made the following trade(s):

• On Wednesday, September 17th, Jason Lettmann acquired 71,163 shares of ALX Oncology stock. The shares were purchased at an average price of $1.08 per share, for a total transaction of $76,856.04.

ALX Oncology Stock Performance

ALX Oncology stock traded up $0.06 during midday trading on Monday, reaching $1.27. The company's stock had a trading volume of 738,990 shares, compared to its average volume of 609,708. ALX Oncology Holdings Inc. has a 52 week low of $0.40 and a 52 week high of $2.08. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.52 and a current ratio of 4.52. The business has a 50-day moving average price of $0.83 and a 200-day moving average price of $0.65.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Analysts expect that ALX Oncology Holdings Inc. will post -2.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered ALX Oncology from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $3.30.

Institutional Trading of ALX Oncology

Several institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new position in shares of ALX Oncology in the 2nd quarter worth $84,000. Acadian Asset Management LLC increased its stake in ALX Oncology by 16.8% during the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company's stock worth $806,000 after acquiring an additional 186,883 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of ALX Oncology by 183.6% during the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company's stock valued at $74,000 after buying an additional 77,065 shares during the period. Almitas Capital LLC boosted its holdings in shares of ALX Oncology by 10.6% in the first quarter. Almitas Capital LLC now owns 1,353,141 shares of the company's stock valued at $843,000 after purchasing an additional 130,196 shares during the period. Finally, Nuveen LLC bought a new position in ALX Oncology in the first quarter worth approximately $103,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.